Moderna, a prominent player in the Covid-19 vaccine market, has reaffirmed its sales outlook for the year. Despite the uncertainty surrounding U.S. vaccination rates, the company remains confident in its projections.
According to Moderna, the outlook provided on Aug. 3 predicts Covid-19 vaccine sales of $6 billion to $8 billion for 2023. Importantly, this forecast already takes into account the fluctuations in vaccination rates in the United States.
Moderna has tailored its expectations to reflect varying scenarios. If 50 million doses of the Covid-19 vaccine are administered in the U.S., the company anticipates sales to fall within the lower half of the projected range. However, if the number of doses administered reaches 100 million, Moderna expects to exceed expectations and achieve sales in the upper half of the range.
To gain a clearer understanding of vaccination trends, Moderna expects to closely monitor uptake and utilization over the coming months. By analyzing full vaccination data through October, the company aims to refine its projections and make more accurate assessments.
It is worth noting that Moderna's announcement follows Pfizer's recent decision to revise its 2023 revenue guidance. Citing decreases in expected sales of its Covid-19 vaccine Comirnaty and treatment Paxlovid, Pfizer adjusted its forecast by a considerable $9 billion.
In conclusion, Moderna's resolute commitment to its sales outlook demonstrates confidence in its product and strategic planning. As the global fight against Covid-19 continues, companies like Moderna play a crucial role in providing vaccines and supporting public health efforts.
Our Latest News
German steel distributor, Kloeckner & Co., sees a surge in shares after announcing a cost-savings initiative and revising its profitability goals. Investors exp...
The performance of U.S. stocks under President Joe Biden compared to previous administrations, concerns about the discrepancy, and future outlook
French trainmaker Alstom reports sales increase in first half driven by rolling stock, but cash flow affected by production ramp up. Order intake also drops.